Nephrology Times
Advertisement
Listen to the discussion of Chapter 18 of Dr. Burton Rose's book, focused on metabolic alkalosis.
A partnership will provide education to primary care clinicians to strengthen identification and treatment of kidney disease.
Otsuka filed a Biologics License Application with the FDA for sibeprenlimab for the treatment of IgA nephropathy (IgAN).
Researchers in China announced that they have performed a successful transplant of a gene-edited pig kidney into a patient.
Research examined the efficacy and safety of lumasiran for primary hyperoxaluria type 1 in infants and toddlers.
Suphamai Bunnapradist discussed the phase 3 TRANSCEND study of felzartamab to treat late AMR after kidney transplantation.
Dosing calculations for carboplatin made using Cockcroft-Gault creatinine clearance may result in excess dosing.
A study explored the association between SCr/CYS ratio and adverse events associated with platinum-based cancer therapies.
NOBLE examined the efficacy and safety of pegcetacoplan in kidney transplant recipients with recurrent C3G or IC-MPGN.
Faith Lynch, president-elect of ANNA, discussed her upcoming term and challenges faced by nephrology nurses.
Impaired kidney function was the primary predictor of hemorrhage among patients treated with anticoagulant apixaban.
Momen Abbasi and Api Chewcharat have been named the 2025 American Kidney Fund Clinical Scientist in Nephrology fellows.
A study examined the association of ankle-brachial index and CKD progression with type 2 diabetes and elevated BMI.
A study examined bone health among a subset of kidney transplant patients from the PROTECT trial of pegloticase for gout.
Could a combined nutritional supplementation and exercise training program improve frailty and health outcomes with CKD?
Researchers examined the association between gout and odds of being wait-listed for a kidney transplant among patients on HD.
Health professionals should promote the benefits of fruits and vegetables, especially to patients receiving dialysis.
Is metformin use ever appropriate for patients with advanced kidney disease and type 2 diabetes?
Oral iptacopan (Fabhalta) has become the first FDA-approved treatment for proteinuria in adults with C3 glomerulopathy.
A study compared stroke and dementia risk between race-free and previous eGFR equations.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.